Document is current
Any future updates will be listed below
-
Authors
Si, Yichen https://orcid.org/0000-0001-5576-3054
Lee, ChangHee
Hwang, Yongha https://orcid.org/0000-0002-4345-581X
Yun, Jeong H.
Cheng, Weiqiu https://orcid.org/0000-0003-4001-8662
Cho, Chun-Seok https://orcid.org/0000-0002-9589-5745
Quiros, Miguel https://orcid.org/0000-0002-0089-3502
Nusrat, Asma
Zhang, Weizhou
Jun, Goo
Zöllner, Sebastian
Lee, Jun Hee https://orcid.org/0000-0002-2200-6011
Kang, Hyun Min https://orcid.org/0000-0002-3631-3979
-
Funding
Funding for this research was provided by:
A. Alfred Taubman Medical Research Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG011031, R01HG011031, R01HG011031)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH2110005)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK133448)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG079163)
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 15 August 2024
First Online: 12 September 2024
Competing interests
: J.H.L. is an inventor on a patent and pending patent applications related to Seq-Scope, which is indirectly relevant to the work presented in this paper. The following disclosures are unrelated to the current study: H.M.K. owns stock in Regeneron Pharmaceuticals; J.H.Y. serves as a consultant for Bridge Biotherapeutics and as a scientific advisory board member for Genentech; C.H.L. began employment with Somite Therapeutics after the initial submission of this manuscript; Y.H. began employment with Samsung Semiconductor after the initial submission of this manuscript. All other authors declare no competing interests.
